Effects of Serotonin Agonist Citalopram on Multimodal Esophageal Stimulation in Healthy Volunteers

Universitaire Ziekenhuizen KU Leuven

Status: Completed

Conditions: Gastroesophageal Reflux

Treatments: Drug: Citalopram; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04355455

Citalopram MuMoS HV

Details and patient eligibility

About

To investigate the effect of citalopram, a selective serotonin reuptake inhibitor, on esophageal sensitivity.

Enrollment: 14 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• HV aged between 18 - 60 years

Exclusion criteria

• history of psychiatric disease or a positive first degree psychiatric family history
• pregnancy or lactation
• concomitant administration of any centrally activating medication (anti-depressive medication, hypnotics, sedatives, anxiolytics, ...)
• medication affecting esophageal motility
• significant co-morbidities (neuromuscular, psychiatric, cardiovascular, pulmonary, endocrine, autoimmune, renal and hepatic)
• prior history of esophageal, gastric surgery or endoscopic anti-reflux procedure
• history of gastrointestinal disease

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

14 participants in 2 patient groups, including a placebo group

Citalopram

Active Comparator group

Description:

Administration of citalopram to assess the esophageal sensitivity in HV

Treatment:

Drug: Citalopram

Placebo

Placebo Comparator group

Description:

Administration of placebo to assess the esophageal sensitivity in HV

Treatment:

Drug: Placebo